›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:PGLNext®
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Konica MinoltaType:
Laboratory Developed Test
Related tests:
PGLNext is a next generation sequencing panel that simultaneously analyzes 14 genes associated with an increased risk of developing paragangliomas (PGLs) and/or pheochromocytomas (PCCs). The testing can be considered at any age in the presence of PGL/PCC with a personal or family history of kidney, thyroid, breast cancer, neurofibromas, kidney, or gastrointestinal stromal tumors (GIST) on the same side of the family.
Cancer:
Glioma
Gene:
EGLN1 (Egl-9 Family Hypoxia Inducible Factor 1), FH (Fumarate Hydratase), KIF1B (Kinesin Family Member 1B), MAX (MYC Associated Factor X), MEN1 (Menin 1), NF1 (Neurofibromin 1)
See More ...
EGLN1 (Egl-9 Family Hypoxia Inducible Factor 1), FH (Fumarate Hydratase), KIF1B (Kinesin Family Member 1B), MAX (MYC Associated Factor X), MEN1 (Menin 1), NF1 (Neurofibromin 1), RET (Ret Proto-Oncogene), SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A), SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2), SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B), SDHC (Succinate Dehydrogenase Complex Subunit C), SDHD (Succinate Dehydrogenase Complex Subunit D), TMEM127 (Transmembrane Protein 127), VHL (von Hippel-Lindau tumor suppressor)
Method:
Next-Generation Sequencing (NGS)
